A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 24305938.
- Also identified by DOI 10.1007/s00268-013-2387-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Historically, completion axillary lymph node dissection (cALND) is recommended in sentinel lymph node (SLN)-positive patients. However, the high rate of negative non-sentinel nodes (NSNs) in cALND and the reported low axillary recurrence rates have led to a more conservative approach. A risk score was developed to identify a patient's individual risk for NSN metastases. Data of 182 SLN-positive patients who underwent cALND were used for risk score development. The risk score, consisting of pathological tumor size (≤ 20/>20 mm), lymphovascular invasion (no/yes), extracapsular extension (no/yes), size of metastases (≤ 2/>2 mm), and number of positive SLNs (1/>1), was subsequently validated on an external population (n = 180). The area under the receiver operating characteristic curve was 0.78 (95 % CI 0.71-0.85) in the original population and 0.78 (95 % CI 0.70-0.85) in the validation population. Based on the predicted risk for positive NSNs, three groups were defined: low risk (≤ 20 %), intermediate risk (21-50 %), and high risk (>50 %). In total, 88 patients met the Z0011 inclusion criteria and none of them had a high predicted risk. Of the 199 non-Z0011 patients, 67 (33.7 %) had low risk, 96 (48.2 %) had intermediate risk, and 36 (18.1 %) had high risk. A simple risk score, integrating just five clinicopathological variables, was developed that may assist in individual decision making regarding ALND in SLN-positive patients outside of the Z0011 trial.
Medical subject headings
- Breast Neoplasms
- Sentinel Lymph Node Biopsy